NYU Langone and NYU Grossman in the News
Teen cancer survivor brings joy to kids in hospitals with activity kits
WABC-TV (New York, NY)
Sammy Wechter, a 17-year-old who was treated for cancer at NYU Langone Health as a child, has launched a nonprofit called A Spark to Inspire. The organization provides non-technological entertainment kits to children facing extended hospital stays. The group has already sent kits to young patients at NYU Langone Health. William L. Carroll, MD, pediatric oncologist at Hassenfeld Children’s Hospital at NYU Langone, who was part of Wechter's care team, noted that such activities provide a significant distraction for pediatric patients.
Also reporting was: Aol
10/21/2026
What to know about the blood clots sidelining NFL star Jalen Hurts
The Washington Post
The article details the blood clots sidelining NFL player Jalen Hurts, distinguishing between superficial vein thrombosis (SVT) and deep vein thrombosis (DVT). Thomas Maldonado, MD, vascular surgeon and director of the Aortic Center at NYU Langone Health, explains that a superficial clot can extend into a deep vein. He notes DVTs are more dangerous as they can dislodge and travel to the lungs, causing a potentially life-threatening pulmonary embolism. Dr. Maldonado adds that an ultrasound is the only definitive way to diagnose any type of blood clot, and he cautions about risks associated with prolonged immobility.
Also reporting was: MSN UK, Yahoo Life
10/21/2026
The NFL owes Jalen Hurts, and all of us, more than haughty dismissiveness *
The Athletic/The New York Times
The NFL is facing criticism for its handling of Philadelphia Eagles quarterback Jalen Hurts’ blood clot injury, which worsened after he played a game and took a long flight. Providing expert analysis on the matter, James Horowitz, MD, director of critical care cardiology at NYU Langone Health, explained that trauma and air travel are key risk factors for blood clots, citing Virchow’s Triad. Dr. Horowitz noted that the vigorous activity involved in a professional football game could create a higher risk of exacerbating such a condition, stating the connection is 'common sense.'
10/21/2026
Dr. Syed Ali Husain on hospital selection and organ transplant wait times
WBBM Newsradio
Syed Ali Husain, MD, MPH, a transplant nephrologist at NYU Langone Health, discusses the complexities patients face when navigating organ transplant waitlists. Following the story of a patient who faced a multi-year delay before transferring facilities, Dr. Husain explains that a patient's choice of hospital heavily influences how quickly they receive a transplant. He notes that these disparities are partly driven by factors within a medical center's control, such as how aggressively individual facilities choose to utilize and transplant available organs.
10/21/2026
Neurologists say Christina Applegate’s multiple sclerosis misdiagnosis is ‘not uncommon’
Prevention
Actress Christina Applegate revealed she was misdiagnosed with multiple sclerosis, which neurologists say is not uncommon. A diagnosis is complex because there is not a single biomarker for MS and other conditions can mimic its symptoms. According to Thomas A. Flagiello, MD, a neurologist at NYU Langone Hospital—Long Island's Multiple Sclerosis Comprehensive Care Center, a diagnosis is based on an 'entire clinical picture,' including a patient's symptoms, MRI results, and spinal fluid analysis, all of which must be interpreted in context. Misdiagnoses can lead to unnecessary treatments while delaying care for the actual underlying condition.
Also reporting was: Aol, Yahoo Health
10/20/2026
Why Christina Applegate’s MS misdiagnosis is so unsettling
Yahoo Entertainment
An article about actress Christina Applegate's reported misdiagnosis with multiple sclerosis highlights the complexities of diagnosing the condition, with estimates suggesting up to 20% of MS diagnoses are incorrect. Multiple experts comment on the diagnostic process, including Josef M. Gutman, MD, director of NYU Langone Hospital—Long Island's Multiple Sclerosis Comprehensive Care Center. He explains that because symptoms can be non-specific, a diagnosis must combine a patient's story with MRI imaging and spinal fluid markers. New diagnostic criteria published in 2023 aim to improve future accuracy.
Also reporting was: Aol
10/21/2026
The One Thing: Natural history studies, diet and the gut, and reimbursement | Episode 3
Ophthalmology Times
A discussion among ophthalmologists highlights several key issues that deserve more attention. Dimitra Skondra, MD, PhD, vice chair of research in the Department of Ophthalmology at NYU Langone Health, argued that the field is not focused enough on the impact of lifestyle, diet, and the gut microbiome on disease progression and treatment response. Other experts pointed to the importance of natural history studies for therapeutic development and the unsustainable future of healthcare reimbursements for expensive, chronic therapies in retina care.
10/21/2026
Blood-based CRC test upgrades improve on precancerous lesion detection
Medscape
Updates to an FDA-approved colorectal cancer blood test have improved the detection of advanced precancerous lesions, according to new research presented by Aasma Shaukat, MD, MPH, the Robert M. and Mary H. Glickman Professor of Medicine and director of outcomes research in the Division of Gastroenterology and Hepatology at NYU Grossman School of Medicine. The study found the updated test showed a sensitivity of 18.2% for these lesions, up from 13.7%. While colonoscopy and stool-based tests remain first-line options, Dr. Shaukat noted the blood test is a consideration for patients who will not proceed with other screening, as it is better than no screening at all.
10/20/2026
Novel blood test detects lung cancer traces long before scans
eCancer
A new study demonstrates that a liquid biopsy can detect lingering traces of non-small-cell lung cancer long before tumors appear on scans, opening a window for timely interventions. Lead investigator Matija Snuderl, MD, director of molecular pathology and professor of pathology at NYU Langone Health, noted that the test bridges the gap between treatment completion and recurrence. Co-lead investigator Harvey I. Pass, MD, the Stephen E. Banner Professor of Thoracic Oncology and professor of surgery at NYU Grossman School of Medicine, added that the findings highlight the test's sensitivity for routine post-treatment monitoring.
Also reporting was: Inside Precision Medicine, Scienmag
10/20/2026
Real-world HIV study allays doubts about long-acting ART injectables
MedPage Today
A real-world study showed that long-acting injectable antiretroviral therapy (ART) effectively maintained virologic suppression for HIV patients, with very low rates of failure. The findings, presented at the IDWeek annual meeting by Ricky K. Hsu, MD, clinical associate professor of medicine at NYU Grossman School of Medicine, came from the OPERA cohort. Among participants who switched to injectable cabotegravir/rilpivirine, 94% had undetectable HIV levels at their last test. Dr. Hsu stated the data demonstrates the therapy is highly efficacious in a real-world setting, which could help increase provider adoption of the treatment.
Also reporting was: MSN UK
10/20/2026
Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
MarketWatch
Moderna and Merck are set to release full Phase 3 trial results for their experimental therapeutic mRNA cancer vaccine, intismeran, used with Keytruda to treat melanoma. Janice Mehnert, MD, director of the Melanoma Medical Oncology Program and associate director of clinical research at NYU Langone’s Perlmutter Cancer Center, a researcher on the trial, described it as a first-in-class approach. While the companies have said the study met its primary endpoints, researchers and investors await the full data to understand the magnitude of the benefit and its potential for other cancers.
10/21/2026
AI breast cancer tools show promise but still need work
WTKR-TV (Norfolk, VA)
Artificial intelligence is increasingly used for breast cancer detection, including a recently FDA-approved tool called Clarity which helps assess future risk. However, the tool has limitations as it is less accurate for Black women and cannot assess women under 50 or over 65. Elizabeth Comen, MD, a medical oncologist at NYU Langone's Perlmutter Cancer Center and co-director of the Mignone Women's Health Collaborative, commented on the rise of breast cancer diagnoses in women under 40, emphasizing the need for improved screening techniques and treatment strategies tailored to younger patients. No hospitals in the Hampton Roads, Virginia area are currently using the Clarity tool.
10/22/2026
14 health systems earn CHIME’s highest digital health designation
Becker's Hospital Review
Fourteen healthcare organizations, including NYU Langone Health, earned the highest designation in the College of Healthcare Information Management Executives’ 2026 Digital Health Most Wired survey. The survey assesses healthcare organizations' digital capabilities across areas like infrastructure, security, interoperability, analytics, and patient engagement. According to CHIME, a level 10 designation recognizes organizations that have successfully integrated digital investments into clinical and operational workflows and have demonstrated measurable value from these technologies.
10/21/2026
What’s in breast milk? New study reveals 7 clues about baby growth
Yahoo
An international study published in Science and led by researchers at NYU Grossman School of Medicine has identified seven molecular markers in breast milk linked to maternal nutrition and infant growth. The research analyzed over 1,500 milk samples from three continents. The molecules, which include four short-chain acylcarnitines, lysine, selenium, and a complex sugar, consistently appeared across diverse populations, creating what researchers called a shared molecular signature. The study presents these as candidate biomarkers, emphasizing they are not yet a diagnostic tool but offer a more nuanced understanding of breast milk's complexity.
10/20/2026
Pollan links psychedelics to loosening the brain's rigid self
Independent Journal Review
This article reviews Michael Pollan's work on psychedelics, highlighting that research quietly restarted at institutions including NYU Langone Health after a long hiatus. It details parallel 2016 trials at NYU Langone Health and Johns Hopkins, where a single psilocybin dose gave significant, lasting anxiety and depression relief to cancer patients. The piece also notes a separate NYU Langone-led trial by Michael P. Bogenschutz, MD, professor in the Department of Psychiatry at NYU Grossman School of Medicine and director of the NYU Langone Center for Psychedelic Medicine, which found psilocybin-assisted therapy substantially reduced heavy drinking, suggesting the drug helps break cognitive rigidity.
10/21/2026
Demodex blepharitis: Diagnosis, treatment response, and recurrence
Ophthalmology Times
Himani Goyal, MD, a cornea specialist and clinical associate professor of ophthalmology at NYU Langone Health, moderated a roundtable discussion on Demodex blepharitis. The forum focused on enhancing diagnosis and expanding treatment options, with specialists discussing recognition and the latest treatment approaches. Dr. Goyal presented a patient case involving recurrent styes, highlighting successful treatment with lotilaner ophthalmic solution, which she described as life-changing for the patient. The group also covered recurrence risk and the importance of awareness across different ophthalmology subspecialties.
10/21/2026
Tolerability remains a TROP2-directed ADC hurdle in EGFR-mutated NSCLC
OncLive
A panel of thoracic oncologists discussed second-line therapy options for EGFR-mutated non-small cell lung cancer after progression on osimertinib-based therapy. The panel was moderated by Elaine Shum, MD, assistant professor of medicine at NYU Langone Health. Experts from Memorial Sloan Kettering Cancer Center, Mount Sinai, and Weill Cornell Medicine weighed the pros and cons of TROP2-directed antibody-drug conjugates versus amivantamab-based regimens. The discussion highlighted that the choice often depends on which agent’s adverse-effect profile a patient can best tolerate, rather than a clear difference in efficacy.
10/21/2026
Multiple factors linked to greater risk of ‘catastrophic’ PCI complication
Cardiovascular Business
New research co-authored by Ramya C. Mosarla, MD, an interventional cardiologist at NYU Langone Health, found that intraprocedural cardiac arrest (IPCA) occurs in nearly 1% of percutaneous coronary intervention (PCI) procedures. Analyzing data from over 3.9 million procedures between 2018 and 2023, the study published in *JACC: Cardiovascular Interventions* reported an overall IPCA rate of 0.93%. Although the rate of IPCA increased slightly over the study period, the risk-adjusted death rate following the complication decreased. The findings may help inform case selection and risk-benefit conversations with patients.
10/21/2026
Travis Kelce shares heartwarming news before Seahawks game
Heavy
Taylor Swift and Travis Kelce donated $26 million to 20 charities before their wedding. Recipients of the donations included Hassenfeld Children’s Hospital at NYU Langone, MSK Kids at Memorial Sloan Kettering Cancer Center, and Children’s Mercy Hospital in Kansas City. City Harvest in New York also received a $1 million donation from the couple, which will help provide food for more than 2.4 million New Yorkers in need. Additionally, Dolly Parton’s Imagination Library received $2 million from the pair.
Also reporting was: Yahoo Sport
10/22/2026
NYU study links GLP-1 weight loss drugs to male pattern baldness
Muscle & Fitness Magazine
New research from NYU Langone Health suggests a direct genetic link between GLP-1 medications and hair loss. Published in the Journal of Investigative Dermatology, the study found that men with a predisposition to androgenetic alopecia have a 7% increased risk of hair loss when using these drugs. This association was previously suspected but not scientifically proven. According to the study’s senior investigator, Lynn Petukhova, PhD, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine, the findings could lead to future screening and combination treatments to prevent hair loss.
10/21/2026
Dr Oberstein on the rationale for evaluating the PD-1/IL-15 fusion protein SAR445877 in MSS CRC
OncLive
Paul E. Oberstein, MD, associate professor in the Department of Medicine at NYU Grossman School of Medicine, service chief of the Gastrointestinal Medical Oncology Program, and assistant director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center, discussed the rationale for an investigational anti–PD-1/IL-15 fusion protein, SAR445877. The agent is being evaluated in microsatellite-stable colorectal cancer, a tumor type that typically shows little response to immunotherapy. He explained that the drug combines a PD-1 checkpoint blockade with an IL-15 cytokine to stimulate the immune system, potentially overcoming resistance in these immunologically 'cold' tumors.
10/21/2026
The $15 billion ad-powered AI startup your doctor may already be using
Ars Technica
The AI-powered search engine OpenEvidence has reached a $15 billion valuation, with reports that nearly two-thirds of US doctors use the tool for patient diagnosis and treatment. Paul A. Testa, MD, chief health informatics officer at NYU Langone Health, explained that the health system is integrating a version of OpenEvidence into its care processes after finding clinicians were already using it. Concurrently, Eric K. Oermann, MD, neurosurgeon at NYU Langone Health, noted the general lack of research into the performance of individual AI tools. The article also mentions partnerships with Mount Sinai Health System and Memorial Sloan Kettering Cancer Center.
10/21/2026
The fitness test that predicts your risk of death
BBC
Heart rate recovery (HRR)—the drop in pulse one minute after exercise—is a strong indicator of cardiovascular health and overall mortality risk. Nieca Goldberg, MD, a cardiologist at NYU Langone Health, explains that a poor HRR can predict high blood pressure and cardiac events. Research indicates that a recovery of fewer than 12 beats per minute is linked to a significantly higher risk of death. Dr. Goldberg recommends that anyone concerned about their HRR should seek a full cardiac risk assessment and notes that regular cardiovascular exercise, like walking or cycling, can improve the metric.
Also reporting was: MSN UK, Yahoo Health
10/21/2026
COVID coverup: FDA suppressing evidence of vaccine’s risks for children
WND
An article alleges that the FDA has suppressed evidence of COVID-19 vaccine risks for children, such as fatal myocarditis, despite internal safety officers recommending label changes. The report claims political interests, pharmaceutical industry influence, and biased media coverage have blocked this information from becoming public. The article states that by failing to disclose risks, the government is not providing patients with informed consent, a point it says was admitted in a recent essay by Arthur L. Caplan, PhD, professor emeritus of population health at NYU Grossman School of Medicine.
10/21/2026
